A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome. 2009

Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
The Linnaeus Centre for Bioinformatics, Uppsala University BMC, Box 598, Husargatan 3, SE-751 24 Uppsala, Sweden.

Reverse transcriptase (RT) is a viral enzyme crucial for HIV-1 replication. Currently, 12 drugs are targeted against the RT. The low fidelity of the RT-mediated transcription leads to the quick accumulation of drug-resistance mutations. The sequence-resistance relationship remains only partially understood. Using publicly available data collected from over 15 years of HIV proteome research, we have created a general and predictive rule-based model of HIV-1 resistance to eight RT inhibitors. Our rough set-based model considers changes in the physicochemical properties of a mutated sequence as compared to the wild-type strain. Thanks to the application of the Monte Carlo feature selection method, the model takes into account only the properties that significantly contribute to the resistance phenomenon. The obtained results show that drug-resistance is determined in more complex way than believed. We confirmed the importance of many resistance-associated sites, found some sites to be less relevant than formerly postulated and-more importantly-identified several previously neglected sites as potentially relevant. By mapping some of the newly discovered sites on the 3D structure of the RT, we were able to suggest possible molecular-mechanisms of drug-resistance. Importantly, our model has the ability to generalize predictions to the previously unseen cases. The study is an example of how computational biology methods can increase our understanding of the HIV-1 resistome.

UI MeSH Term Description Entries

Related Publications

Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
September 2006, Medicinal chemistry (Shariqah (United Arab Emirates)),
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
June 2007, Applied microbiology and biotechnology,
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
March 2023, Molecules (Basel, Switzerland),
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
December 2013, Future medicinal chemistry,
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
November 1988, Science (New York, N.Y.),
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
January 2008, Advances in pharmacology (San Diego, Calif.),
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
January 2000, Advances in pharmacology (San Diego, Calif.),
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
April 2004, Vaccine,
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
April 2001, Analytical biochemistry,
Marcin Kierczak, and Krzysztof Ginalski, and Michał Dramiński, and Jacek Koronacki, and Witold Rudnicki, and Jan Komorowski
March 2005, Journal of medicinal chemistry,
Copied contents to your clipboard!